Journals – 2018


Falanga A, Iachetta G, Lombardi L, et al. Enhanced uptake of gH625 by blood brain barrier compared to liver in vivo: characterization of the mechanism by an in vitro model and implications for delivery. Sci Rep. 2018;8(1):13836. [PubMed]
de A, Falanga A, Galdiero S, Guida M, Maselli V, Galdiero E. Genotoxicity of gold nanoparticles functionalized with indolicidin towards Saccharomyces cerevisiae. J Environ Sci (China). 2018;66:138-145. [PubMed]
Falanga A, Mercurio F, Siciliano A, et al. Metabolomic and oxidative effects of quantum dots-indolicidin on three generations of Daphnia magna. Aquat Toxicol. 2018;198:158-164. [PubMed]
Ben D, David S, Hervé-Aubert K, et al. Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. Eur J Pharm Biopharm. 2018;131:99-108. [PubMed]
Falanga A, Galdiero S. Peptide chemistry encounters nanomedicine: recent applications and upcoming scenarios in cancer. Future Med Chem. 2018;10(16):1877-1880. [PubMed]
de A, Lombardi L, Falanga A, et al. Polymicrobial antibiofilm activity of the membranotropic peptide gH625 and its analogue. Microb Pathog. 2018;125:189-195. [PubMed]
Tudisco C, Cambria M, Giuffrida A, et al. Comparison Between Folic Acid and gH625 Peptide-Based Functionalization of Fe<sub>3</sub>O<sub>4</sub> Magnetic Nanoparticles for Enhanced Cell Internalization. Nanoscale Res Lett. 2018;13(1):45. [PubMed]
de A, Maselli V, Falanga A, et al. Efficiency of gold nanoparticles coated with the antimicrobial peptide indolicidin against biofilm formation and development of <i>Candida</i> spp. clinical isolates. Infect Drug Resist. 2018;11:915-925. [PubMed]